Arcus Biosciences, Inc. (RCUS)

Over the past six months, Arcus Biosciences' stock has experienced several notable events. In October 2025, the stock surged due to investor confidence in its pipeline candidates, and positive data was presented from the ARC-20 and EDGE-Gastric studies. Taiho Pharmaceutical exercised its option for an exclusive license to casdatifan. Analyst firms adjusted their ratings and price targets for RCUS. In September 2025, CAO Alexander Azoy sold shares of company stock. In August 2025, the company reported Q2 earnings and Wall Street Zen raised Arcus Biosciences from a "strong sell" rating to a "hold" rating. In July 2025, Quemliclustat received Orphan Drug Designation from the U.S. Food and Drug Administration. In June 2025, Arcus Biosciences, in collaboration with Gilead Sciences, completed patient enrollment for STAR-221. In May 2025, data from the ARC-20 study was presented at the ASCO Annual Meeting. In February 2025, Arcus completed a $150 million financing and reported $992 million in cash, cash equivalents, and marketable securities.

As a clinical-stage biopharmaceutical company, Arcus Biosciences' products are in the research and development phase and are not yet commercialized. Therefore, the concept of demand seasonality does not directly apply. The demand for its investigational products is driven by the progression of clinical trials, regulatory approvals, and the unmet medical needs in oncology. The company's revenue streams are primarily from license and development service revenues, largely from its collaboration with Gilead Sciences.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapies in the United States. The company aims to enhance the immune system's ability to combat cancer by targeting the tumor microenvironment and immune system. Its pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Casdatifan, AB598, AB801, AB928, AB122, and AB680, which are in various stages of clinical trials.

Arcus Biosciences, Inc. is headquartered in Hayward, California, USA. The company conducts clinical trials in the United States and has employees across six continents, including North America, Asia, and Europe. Its collaboration with Gilead Sciences involves global studies.

Arcus Biosciences' brand reputation is tied to its clinical trial progress and strategic partnerships. Positive clinical trial results and collaborations with major pharmaceutical companies contribute positively to its reputation. The orphan drug designation for quemliclustat also highlights the company's commitment to addressing unmet medical needs. However, the competitive nature of the immuno-oncology field and past disappointments in TIGIT programs could pose reputational challenges. Insider stock sales could also be perceived negatively by some investors.

Arcus Biosciences, Inc. has a mixed ownership structure, with significant holdings by institutional, retail, and individual investors. Institutional investors and hedge funds own a substantial portion of the company's stock. Major institutional owners include Gilead Sciences Inc., BlackRock, Inc., and Vanguard Group Inc., among others.